This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
The purpose of this notice is to inform the public about a meeting of the NIH Blue Ribbon Panel to Advise on the Risk Assessment of the National Emerging Infectious Diseases Laboratories at the Boston University Medical Campus. The meeting will be held Tuesday, October 5, 2010 at the Mainstage at Roxbury Community College, 1234 Columbus Avenue, Roxbury, MA from approximately 6:30 p.m. to 10 p.m.
This public meeting is being held to provide an update to the community on the status and proposed approach of the risk assessment for the BUMC NEIDL. The meeting program will include an update and review of the ongoing supplementary risk assessment study as well as opportunity for oral public comment. In addition, at any time, members of the public may file written comments to the following address: NIH Blue Ribbon Panel, Office of the Director, National Institutes of Health, Mail Stop Code 7985, Bethesda, MD 20892-7985 or by sending an e-mail to: firstname.lastname@example.org.
An agenda and slides for the meeting will be posted to the NIH Blue Ribbon Panel Web site in advance of the meeting at: http://nihblueribbonpanel-bumc-neidl.od.nih.gov/. For additional information concerning this meeting, contact Ms. Kelly Fennington, Senior Health Policy Analyst, Office of Biotechnology Activities, Office of Science Policy, Office of the Director, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892-7985; telephone 301-496-9838; e-mail email@example.com.Start Signature
Dated: September 1, 2010.
Amy P. Patterson,
Acting Director, Office of Science Policy, National Institutes of Health.
[FR Doc. 2010-22323 Filed 9-7-10; 8:45 am]
BILLING CODE 4140-01-P